Residual Stenosis and Restenosis Following Carotid Endarterectomy With Primary Closure, A Prospective Tracking Study
Launched by CHARLES UNIVERSITY, CZECH REPUBLIC · Jun 30, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how often and when narrowing of the carotid artery (a main artery in the neck that supplies blood to the brain) happens or returns after a common surgery called carotid endarterectomy (CEA). This surgery is done to remove blockages and help prevent strokes. The study will follow patients who have this surgery using a specific method called primary closure, to see how well it works over time and if any narrowing remains or comes back within a year after surgery.
People who might join this study are adults between 18 and 90 years old who are having elective carotid endarterectomy and do not have certain health issues like previous similar surgeries, high surgical risk, or specific nerve problems in the neck. Participants will have scans before surgery, then again about one month and one year after, to check their artery’s condition. The study will also watch for any complications like stroke or heart problems. This research is being done in several centers in the Czech Republic, using the same surgery and testing methods, to provide clear information on how safe and effective this surgery technique is in the long run.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients without matching any of exclusion criteria who underwent cartotid endarterectomy
- Exclusion Criteria:
- • Age ≤18 or ≥90 years
- • Previous endarterectomy or stenting
- • Unsuitable vascular anatomy
- • High perioperative risk
- • Contralateral cranial nerve X or XII palsy
- • History of neck irradiation
- • Tandem carotid stenosis or intracranial vascular pathology (e.g., aneurysm or AVM)
- • Absence of signed informed consent
About Charles University, Czech Republic
Charles University, located in the Czech Republic, is a prestigious institution renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive academic expertise and state-of-the-art facilities to conduct innovative research that aims to improve patient outcomes and contribute to the global medical community. With a focus on ethical standards and rigorous scientific methodologies, Charles University collaborates with various stakeholders to explore new therapies and enhance healthcare practices, fostering a culture of excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Prague, , Czechia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported